We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Paves the Way for Global Digital Health Expansion
Read MoreHide Full Article
Key Takeaways
HIMS acquires ZAVA, gaining 1.3 million users and access to U.K., Germany, France and Ireland markets.
HIMS to enter Canada, offering a low-cost weight loss program with generic semaglutide.
HIMS scales globally through acquisitions and local care to lead in chronic digital health treatment.
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , has taken significant strides in international expansion as a strategic lever to boost its business. A central milestone was the acquisition of ZAVA, a European digital health platform with operations across the U.K., Germany, France and Ireland. This acquisition, announced in June 2025, grants Hims & Hers access to over 1.3 million active customers and nearly 2.3 million consultations delivered in 2024 by ZAVA’s in-house medical team. The integration of ZAVA’s technology with Hims & Hers’ established brand positions it to deliver personalized, seamless digital healthcare across key European markets.
Building on this momentum, Hims & Hers announced a planned entry into the Canadian market, timed with the global debut of generic semaglutide — a major breakthrough for affordable obesity treatment. The Canadian expansion will allow the company to offer its holistic weight loss program at significantly lower costs compared to existing branded options. By combining digital accessibility, 24/7 provider support and reduced drug costs, Hims & Hers aims to transform weight loss care for Canadians, especially as nearly two-thirds of the adult population struggles with overweight or obesity issues.
These expansions reflect a clear growth roadmap leveraging both strategic acquisitions and organic scaling. By investing in localized care delivery, multilingual provider networks and category leadership in chronic condition treatment, Hims & Hers is effectively transforming from a U.S.-centric platform into a global digital health leader.
TDOC & AMWL’s Global Expansion Moves
Teladoc Health, Inc. (TDOC - Free Report) has established a strong international presence by leveraging its technology and partnerships to support operations across Europe, South America and Asia, anchored by its Barcelona headquarters. Teladoc Health has extended its offerings globally through white-labeled and co-branded partnerships, notably with telecommunications companies and insurers, delivering localized services using regional languages and currencies. To strengthen its international capabilities, Teladoc Health acquired Catapult Health in first-quarter 2025. Through localized offerings by BetterHelp and robust global distribution channels, Teladoc Health continues to deepen its reach in key non-U.S. markets.
American Well Corporation (AMWL - Free Report) , popularly known as Amwell, has expanded internationally through focused partnerships and product innovation. Amwell's global footprint was significantly enhanced with its SilverCloud by Amwell offering, extending its reach in the behavioral health space to international markets valued at approximately $23 billion. Additionally, Amwell’s collaboration with Hello Heart and joint venture with Cleveland Clinic (The Clinic) demonstrate its strategic approach to global expansion by leveraging alliances that enrich its hybrid care platform and allow integration of best-in-class services.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 96.8% year to date, outperforming the industry’s growth of 6.2%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 4.1X is lower than the industry’s average of 5.5X, but is higher than its three-year median of 2.3X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 177.8% improvement from 2024.
Image: Bigstock
Hims & Hers Paves the Way for Global Digital Health Expansion
Key Takeaways
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , has taken significant strides in international expansion as a strategic lever to boost its business. A central milestone was the acquisition of ZAVA, a European digital health platform with operations across the U.K., Germany, France and Ireland. This acquisition, announced in June 2025, grants Hims & Hers access to over 1.3 million active customers and nearly 2.3 million consultations delivered in 2024 by ZAVA’s in-house medical team. The integration of ZAVA’s technology with Hims & Hers’ established brand positions it to deliver personalized, seamless digital healthcare across key European markets.
Building on this momentum, Hims & Hers announced a planned entry into the Canadian market, timed with the global debut of generic semaglutide — a major breakthrough for affordable obesity treatment. The Canadian expansion will allow the company to offer its holistic weight loss program at significantly lower costs compared to existing branded options. By combining digital accessibility, 24/7 provider support and reduced drug costs, Hims & Hers aims to transform weight loss care for Canadians, especially as nearly two-thirds of the adult population struggles with overweight or obesity issues.
These expansions reflect a clear growth roadmap leveraging both strategic acquisitions and organic scaling. By investing in localized care delivery, multilingual provider networks and category leadership in chronic condition treatment, Hims & Hers is effectively transforming from a U.S.-centric platform into a global digital health leader.
TDOC & AMWL’s Global Expansion Moves
Teladoc Health, Inc. (TDOC - Free Report) has established a strong international presence by leveraging its technology and partnerships to support operations across Europe, South America and Asia, anchored by its Barcelona headquarters. Teladoc Health has extended its offerings globally through white-labeled and co-branded partnerships, notably with telecommunications companies and insurers, delivering localized services using regional languages and currencies. To strengthen its international capabilities, Teladoc Health acquired Catapult Health in first-quarter 2025. Through localized offerings by BetterHelp and robust global distribution channels, Teladoc Health continues to deepen its reach in key non-U.S. markets.
American Well Corporation (AMWL - Free Report) , popularly known as Amwell, has expanded internationally through focused partnerships and product innovation. Amwell's global footprint was significantly enhanced with its SilverCloud by Amwell offering, extending its reach in the behavioral health space to international markets valued at approximately $23 billion. Additionally, Amwell’s collaboration with Hello Heart and joint venture with Cleveland Clinic (The Clinic) demonstrate its strategic approach to global expansion by leveraging alliances that enrich its hybrid care platform and allow integration of best-in-class services.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 96.8% year to date, outperforming the industry’s growth of 6.2%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 4.1X is lower than the industry’s average of 5.5X, but is higher than its three-year median of 2.3X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 177.8% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.